West Broward Outpatient Clinic
Welcome,         Profile    Billing    Logout  
 5 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kakar, Rishi
NCT06608641: Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Recruiting
3
490
US
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Jina Pharmaceuticals Inc., Novum Pharmaceutical Research Services
Bipolar 1 Disorder
06/25
09/25
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Active, not recruiting
2
350
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
05/25
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
10/25
10/25
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting
N/A
300
Canada, US, RoW
ERG assessment (RSPA)
diaMentis Inc.
Schizophrenia, Bipolar I Disorder
12/24
12/24
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
Peters, Ashild
NCT05372887: Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

Withdrawn
2
220
RoW
TNX-102 SL, Low dose cyclobenzaprine sublingual tablets, Placebo, Placebo sublingual tablets
Tonix Pharmaceuticals, Inc.
PTSD
11/22
11/22
UPLIFT, NCT05686408: Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Completed
2
132
US
TNX-601 ER, Tianeptine, Placebo
Tonix Pharmaceuticals, Inc., Rho, Inc.
Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
09/23
09/23
Watson, Kadian
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23

Download Options